Skip to main content

The Hazardous Waste Source Reduction and Management Review Act of 1989

BayBiotech.NET

The Hazardous Waste Source Reduction and Management Review Act of 1989 applies to large quantity generators that produce more than 12,000 kilograms (13.2 tons) of hazardous waste, or 12 kilograms (26 pounds) of extremely hazardous waste, in 1990 and every four years thereafter. The law requires the generator companies of such hazardous waste to:
• Conduct a source reduction evaluation of their facilities and prepare the following:

 Source Reduction Evaluation Review and Plan (Plan)

 Hazardous Waste Management Performance Report (Report)

 Summary Progress Report (SPR)

• Implement feasible methods for reducing the quantity and/or the hazardous characteristics of routinely generated hazardous waste.

The main purpose of requiring generators to review and implement source reduction practices is to reduce the quantity of hazardous waste generated in California and thereby to promote public health and safety and to improve environmental quality.
Such a source reduction can also help large quantity generators to become more efficient in their use of resources.
The Plan must also include a list of potential source reduction measures for major waste streams, and describe the efforts taken to evaluate these measures. Major waste streams are defined as those waste streams that exceed five percent of the total weight of routinely generated hazardous wastes. Such major waste streams can fall under one of three categories:

• Category A: hazardous wastes that are processed through an on-site wastewater treatment unit prior to discharge to a publicly owned treatment works (POTW) or to receiving water under a National Pollution Discharge Elimination System (NPDES) permit.

• Category B: all other hazardous wastes that is not processed in a wastewater treatment unit.

• Category C: all wastes that are classified as extremely hazardous wastes.

Please click here to understand more about The Hazardous Waste Source Reduction and Management Review Act of 1989.

Comments

Post a Comment

Popular posts from this blog

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!
Post a Comment
Read more

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...
Post a Comment
Read more

Risk Based Clinical Monitoring

BayBiotech.NET FDA's recommendation of Risk Based Monitoring of Clinical Trials , as published in their Draft Guidance in August 2011. For the first time, FDA provided guidance on monitoring of clinical investigations in 1988 which was recently withdrawn, stated that the “most effective way” to monitor an investigation was to “maintain personal contact between the monitor and the investigator throughout the clinical investigation.” At the time the guidance was issued, sponsors had only limited ways to effect meaningful communication with investigators other than through on-site visits.   This guidance recommends an assessment by the sponsor for the need of 100% on-site monitoring. Such an assessment may be based on the complexity of the study protocol and not be generally applicable to all trial types. It explains the importance of remote monitoring facilitated by the use of electronic data capture system (EDC) and also emphasizes the need of the identifying crit...
1 comment
Read more